Influenza Vaccines Market Report 2026

The influenza vaccines market size has grown strongly in recent years. It will grow from $9.04 billion in 2025 to $9.71 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rising prevalence of seasonal influenza, limited public awareness in early 2000s, predominance of trivalent vaccines, low global manufacturing capacity, reliance on traditional egg-based production methods.

The influenza vaccines market size is expected to see strong growth in the next few years. It will grow to $13.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing adoption of quadrivalent vaccines, expansion of precision medicine approaches, growing government vaccination initiatives, development of cell-based and recombinant vaccines, enhanced cold chain and distribution infrastructure. Major trends in the forecast period include seasonal vaccine formulation optimization, expansion of pediatric immunization programs, increase in government-funded flu vaccination campaigns, adoption of novel adjuvants for enhanced immunogenicity, growth in home-based and outpatient vaccine delivery.

The increasing incidence of seasonal influenza is anticipated to drive the growth of the influenza vaccine market in the coming years. Seasonal influenza is a contagious respiratory illness caused by influenza viruses that circulate predominantly during certain periods of the year, most often in colder seasons. The rising burden of seasonal influenza is associated with factors such as antigenic drift, heightened population susceptibility, environmental influences, incomplete vaccine coverage, and the absence of universal immunization. Influenza vaccines play a critical role in lowering the incidence of seasonal influenza by providing protection against the virus strains expected to circulate each season. For example, in November 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, the 2022-2023 flu season in the United States resulted in approximately 31 million influenza-related illnesses, 14 million medical visits, 360,000 hospitalizations, and 21,000 deaths. As a result, the growing incidence of seasonal influenza is contributing to the expansion of the influenza vaccine market.

Major companies operating in the influenza vaccine market are focusing on advanced product innovations, such as quadrivalent seasonal influenza vaccines, to strengthen their respiratory vaccine portfolios and overall financial performance. Quadrivalent seasonal influenza vaccines are formulated to protect against four influenza virus strains, including two influenza A strains and two influenza B strains. For instance, in September 2023, Clover Biopharmaceuticals Ltd., a China-based biotechnology company, launched AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine. This product is the only imported quadrivalent seasonal influenza vaccine approved in China for individuals aged three years and older. Its quadrivalent formulation enhances vaccine effectiveness by offering broader protection, particularly against varying influenza B strains, compared with trivalent vaccines.

In February 2023, Clover Biopharmaceuticals Ltd. partnered with Adimmune Corporation to exclusively commercialize AdimFlu-S (QIS) in mainland China. Through this partnership, Clover aims to expand its respiratory vaccine franchise by leveraging its established commercial infrastructure to distribute a high-quality quadrivalent influenza vaccine and meet the rising demand for influenza prevention in the Chinese market. Adimmune Corporation is a Taiwan-based vaccine manufacturer engaged in the development and production of essential vaccines.

Major companies operating in the influenza vaccines market are Pfizer Inc., Merck & Co Inc., Sanofi-Aventis LLC, GlaxoSmithKline plc, Serum Institute of India Private Limited, Seqirus Inc., CSL Limited, Daiichi Sankyo Company Limited, Moderna Inc., Novavax AB, Bharat Biotech International Limited, Valneva SE, Shionogi & Co Ltd., Sinovac Biotech Co Ltd., Walvax Biotechnology Co Ltd., Hualan Biological Engineering Inc., China National Pharmaceutical Group Corporation, Green Cross Corporation, Mitsubishi Tanabe Pharma Corporation, Osivax, Vaxess Technologies Inc., Gamma Vaccines Pty Ltd.

North America was the largest region in the influenza vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the influenza vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the influenza vaccines market by increasing import costs for raw materials, vials, syringes, and specialized manufacturing equipment. This has led to higher production costs, particularly impacting quadrivalent vaccine segments and regions like Asia-Pacific and Europe where significant vaccine manufacturing hubs exist. While tariffs create cost pressures and supply chain disruptions, they have also incentivized manufacturers to localize production and invest in domestic vaccine facilities, potentially boosting regional vaccine security and self-sufficiency.

The influenza vaccines market research report is one of a series of new reports that provides influenza vaccines market statistics, including influenza vaccines industry global market size, regional shares, competitors with a influenza vaccines market share, detailed influenza vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the influenza vaccines industry. This influenza vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Influenza vaccines are flu vaccines developed to provide immunity against influenza viruses. These vaccines are often quadrivalent formulations designed to protect against four different influenza strains, including two influenza A viruses and two influenza B viruses.

The main types of influenza vaccines include inactivated vaccines and live attenuated vaccines. Inactivated vaccines contain killed or inactivated viruses that stimulate an immune response without causing disease and are used to prevent infection and lessen the severity of illness caused by influenza viruses. These vaccines are available in quadrivalent and trivalent formulations and are administered through injections and nasal sprays for both pediatric and adult populations. They are distributed through hospitals and pharmacies, government and institutional supply channels, and other distribution networks.

The influenza vaccines market consists of sales of recombinant influenza vaccines, high-dose influenza vaccines, cell-based influenza vaccines, and egg-based influenza vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.